Congrats to my colleagues for this interesting analysis.
Looking at patients who met DOTS criteria and receive dalbavancin in our hospital, they differ from the DOTS trial
Younger, more IDU, more R-sided IE (less SSTI), and more persistent bacteremia.
Yet, outcomes similar #IDSky
Jonathan Ryder, MD
In clinical practice, patients with #Bacteremia receiving dalbavancin were younger and more likely to have substance use or housing instability than those in the DOTS trial, but completed therapy with similar low failure rates. ja.ma/4odctAk
